The Future of the RTS,S/AS01 Malaria Vaccine: An Alternative Development Plan

1. RTS,S Clinical Trials Partnership (2015) Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386: 31–45. doi: 10.1016/S0140-6736(15)60721-8 25913272

2. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, et al. (1997) A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 336: 86–91. 8988885

3. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, et al. (2001) Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358: 1927–1934. 11747915

4. Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, et al. (2008) Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med 359: 2533–2544. doi: 10.1056/NEJMoa0807773 19064623

5. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, et al. (2004) Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364: 1411–1420. 15488216

6. Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, et al. (2007) Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 370: 1543–1551. 17949807

7. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, et al. (2008) Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 359: 2521–2532. doi: 10.1056/NEJMoa0807381 19064627

8. Gulland A (2015) Malaria vaccine difficult to roll out because four doses are needed, WHO says. BMJ 351: h5706. doi: 10.1136/bmj.h5706 26502887

9. The World Bank (2014) World Development Indicators: Health Systems. http://wdi.worldbank.org/table/2.15 Last accessed 30 October 2015. Washington, DC.

10. European Medicines Agency (2015) First malaria vaccine receives positive scientific opinion from EMA EMA/CHMP/488348/2015. Press_Office, editor. London. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2015/07/WC500190447.pdf

11. WHO (2015) Meeting of the Strategic Advisory Group of Experts on immunization, October 2015 –conclusions and recommendations. Wkly Epidemiol Rec 90: 681–699. 26685390

12. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, et al. (2015) The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature 526: 207–211. doi: 10.1038/nature15535 26375008

13. Ceesay SJ, Casals-Pascual C, Erskine J, Anya SE, Duah NO, et al. (2008) Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. Lancet 372: 1545–1554. doi: 10.1016/S0140-6736(08)61654-2 18984187

14. O'Meara WP, Bejon P, Mwangi TW, Okiro EA, Peshu N, et al. (2008) Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet 372: 1555–1562. doi: 10.1016/S0140-6736(08)61655-4 18984188

15. Neafsey DE, Juraska M, Bedford T, Benkeser D, Valim C, et al. (2015) Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. N Engl J Med 373: 2025–2037. doi: 10.1056/NEJMoa1505819 26488565

16. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, et al. (2014) Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 371: 411–423. doi: 10.1056/NEJMoa1314981 25075834

17. Cotter C, Sturrock HJ, Hsiang MS, Liu J, Phillips AA, et al. (2013) The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet 382: 900–911. doi: 10.1016/S0140-6736(13)60310-4 23594387

18. Bousema T, Griffin JT, Sauerwein RW, Smith DL, Churcher TS, et al. (2012) Hitting hotspots: spatial targeting of malaria for control and elimination. PLoS Med 9: e1001165. doi: 10.1371/journal.pmed.1001165 22303287

19. Foege W (2011) Lessons and innovations from the West and Central African Smallpox Eradication Program. Vaccine 29 Suppl 4: D10–12. doi: 10.1016/j.vaccine.2011.04.008 22188932

20. Foege WH, Millar JD, Lane JM (1971) Selective epidemiologic control in smallpox eradication. Am J Epidemiol 94: 311–315. 5110547

21. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, et al. (2015) Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386: 857–866. doi: 10.1016/S0140-6736(15)61117-5 26248676

22. White MT, Verity R, Griffin JT, Asante KP, Owusu-Agyei S, et al. (2015) Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis 15: 1450–1458. doi: 10.1016/S1473-3099(15)00239-X 26342424

23. Youngster I, Barnett ED. (2016) Interactions among Travel Vaccines & Drugs. In: Centers for Disease Control and Prevention. Travelers' Health. Chapter 2: The Pre-Travel Consultation. http://wwwnc.cdc.gov/travel/yellowbook/2016/the-pre-travel-consultation/interactions-among-travel-vaccines-drugs.